98%
921
2 minutes
20
Unlabelled: Vitamin D intake over the recommended dose is usually associated with high serum 25(OH)D levels and generally not associated with symptoms of hypercalcemia. High doses of cholecalciferol need to be avoided to protect against vitamin D toxicity and related complications. Strict adherence to the clinical guidelines for treating vitamin D deficiency can ensure safe and effective treatment.
Purpose: We observed a tendency to use high doses of cholecalciferol for vitamin D deficiency treatment or vitamin D supplementation. We aimed to determine the biochemical characteristics of patients with high normal and elevated serum 25(OH)D levels.
Methods: An online invitation was sent to all tertiary endocrinology clinics in Turkey to complete an online retrospective survey (DeVIT-TOX Survey) for patients diagnosed with high serum 25(OH)D levels (> 88 ng/mL) between January 2019 and December 2019. The patients were evaluated according to the presence of signs and symptoms of hypercalcemia and doses of vitamin D intake, evaluated into the following three groups according to their 25(OH)D levels: group 1, > 150 ng/mL; group 2, 149-100 ng/mL; and group 3, 99-88 ng/mL.
Results: A total of 253 patients were included in the final analysis (female/male: 215/38; mean age, 51.5 ± 15.6 years). The average serum 25(OH)D level was 119.9 ± 33 (range, 88-455) ng/mL, and the average serum calcium level was 9.8 ± 0.7 (range, 8.1-13.1) mg/dL. Most (n = 201; 75.4%) patients were asymptomatic despite having high serum 25(OH)D and calcium levels. The serum 25(OH)D level was significantly higher in the symptomatic groups than in the asymptomatic groups (138.6 ± 64 ng/mL vs. 117.7 ± 31 ng/mL, p < 0.05). The most common cause (73.5%) associated with high serum 25(OH)D levels was the inappropriate prescription of a high dose of oral vitamin D (600.000-1.500.000 IU) for treating vitamin D deficiency/insufficiency in a short time (1-3 months). The cut-off value of 25 (OH) D level in patients with hypercalcemia was found to be 89 ng/mL [median 116.5 (89-216)].
Conclusions: High dose of vitamin D intake is associated with a high serum 25 OH D level, without symptoms of hypercalcemia. Inappropriate prescription of vitamin D is the primary cause for elevated 25(OH) D levels and related hypercalcemia. Hypercalcemia may not be observed in every patient at very high 25(OH) D levels. Adherence to the recommendation of guidelines is essential to ensure safe and effective treatment of vitamin D deficiency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11657-021-01002-8 | DOI Listing |
Clin Nutr ESPEN
September 2025
Department of Nutrition, Graduate School of Human Life and Ecology, Osaka Metropolitan University, 2-1-132, Osaka-shi, Osaka 536-8525, JAPAN; Department of Endocrinology and Metabolism, Hospital, National Center for Geriatrics and Gerontology, 7-430 Moriokachō, Obu, Aichi, 474-0038, Japan. Electron
Background & Aims: Vitamin D deficiency has been associated with cognitive decline and Alzheimer's disease (AD); however, findings remain inconsistent. Assessing vitamin D status based solely on total 25-hydroxyvitamin D [25(OH)D] may be insufficient, and other metabolites, such as 24,25-dihydroxyvitamin D [24,25(OH)D] and 3-epimer-25-hydroxyvitamin D [3-epi-25(OH)D], may provide additional insights. This study aimed to examine the association between serum vitamin D metabolite concentrations and cognitive function in older adults.
View Article and Find Full Text PDFBMC Endocr Disord
September 2025
Department of Endocrinology and Metabolism, Jiangxi Medical College, The Second Affiliated Hospital, Nanchang University, Nanchang City, 330006, Jiangxi Province, China.
Objective: To investigate the association between thyroid hormone sensitivity indices and bone metabolism markers in newly diagnosed middle-aged and elderly type 2 diabetes mellitus (T2DM) patients with normal thyroid function.
Method: We retrospectively analyzed 350 newly diagnosed T2DM patients (≥ 45 years), stratified by bone mineral density into Group A (normal bone density group) and Group B (low bone mass and osteoporosis group). General data and clinical biochemical parameters were collected: free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), osteocalcin (OC), bone-specific alkaline phosphatase (BALP), serum calcium (Ca), serum phosphorus (P), fasting plasma glucose (FPG), glycosylated hemoglobinA1c (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum creatinine (SCr), serum uric acid (SUA), and estimated Glomerular Filtration Rate (eGFR).
Front Endocrinol (Lausanne)
September 2025
Molecular Testing Laboratory, Department of Medical Laboratory Sciences, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.
Background And Objectives: The Coronavirus disease 2019 (COVID-19) pandemic underscored the importance of identifying host factors that influence susceptibility to infection. Vitamin D signaling, mediated via its receptor (), along with innate immune mediators such as antimicrobial peptides (e.g.
View Article and Find Full Text PDFReprod Health
September 2025
Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Disorders, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Background: Suboptimal 25-hydroxyvitamin D (25OHD) during pregnancy can have adverse maternal and neonatal outcomes.
Aim: This study aimed to estimate the prevalence of vitamin D deficiency in pregnant females in Lebanon and to identify its risk factors.
Methods: This is a cross-sectional study involving pregnant females identified during their first-early second trimester visit to obstetricians in two centers in Beirut.
Front Endocrinol (Lausanne)
September 2025
Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Tianjin Eye Institute, Tianjin, China.
Introduction: Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older adults, with significant inter-individual variability in clinical progression. Vitamin D, known for its role in calcium homeostasis and anti-inflammatory pathways, may be implicated in AMD pathogenesis. This study aimed to investigate serum 25-hydroxyvitamin D [25(OH)D] levels in AMD patients and their association with clinical phenotypes.
View Article and Find Full Text PDF